NUTROPIN Drug Profile

Summary for Tradename: NUTROPIN

High Confidence Patents:	0
Applicants:	2
BLAs:	2
Drug Prices:	Drug price information for NUTROPIN
Recent Clinical Trials:	See clinical trials for NUTROPIN

See drug prices for NUTROPIN

Recent Clinical Trials for NUTROPIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Rochester	Phase 1
Genentech, Inc.	Phase 4
Center for Human Reproduction	Phase 1/Phase 2

See all NUTROPIN clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NUTROPIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NUTROPIN Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for NUTROPIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	NUTROPIN	somatropin	For Injection	020168		2036-12-20	Patent claims search
Genentech, Inc.	NUTROPIN	somatropin	For Injection	020168		2036-04-08	Patent claims search
Genentech, Inc.	NUTROPIN	somatropin	For Injection	020168		2034-02-06	Patent claims search
Genentech, Inc.	NUTROPIN	somatropin	For Injection	020168		2037-11-28	Patent claims search
Genentech, Inc.	NUTROPIN	somatropin	For Injection	020168		2036-12-21	Patent claims search

Market Dynamics and Financial Trajectory for NUTROPIN

Last updated: April 12, 2026

What Is the Market Position of NUTROPIN?

NUTROPIN is a brand of human growth hormone (hGH) biosimilar or recombinant biologic product, primarily used for growth hormone deficiency, idiopathic short stature, and other growth-related conditions. Manufactured by Novo Nordisk, NUTROPIN operates within a competitive landscape of biologic and biosimilar endocrine therapies.

Market Overview and Growth Drivers

Key Market Segments

• Endocrinology: Focused on growth hormone deficiency.
• Pediatric Use: Predominantly prescribed for children with growth delays.
• Adult Use: For adults with growth hormone deficiency.
• Geographic Regions: The highest demand in North America, Europe, and parts of Asia-Pacific, driven by healthcare infrastructure and regulatory approvals.

Market Size and Growth Rate

The global growth hormone market was valued at approximately USD 4.9 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.8% from 2023 to 2030 (Grand View Research, 2023).

Year	Estimated Market Size (USD billion)
2023	5.2
2025	6.1
2030	8.2

Key Drivers

• Increasing diagnosis rates of growth hormone deficiency.
• Expanding approval of biosimilar growth hormones to reduce treatment costs.
• Growing awareness of growth disorders among pediatric populations.
• Improved healthcare infrastructure facilitating access in emerging markets.

Challenges

• High treatment costs limit access in lower-income regions.
• Patent expirations have introduced biosimilar competitors, impacting NUTROPIN’s pricing power.
• Regulatory hurdles differing across jurisdictions influence market penetration and commercialization timelines.
• Safety concerns and varying clinical guidelines affect prescribing behaviors.

Competitive Landscape

NUTROPIN faces competition from several biologic and biosimilar growth hormones, including:

• Eli Lilly's Genotropin
• Pfizer’s Somatropin
• Sandoz’s Omnitrope (biosimilar)
• Ipsen’s Omnitrope (biosimilar)

Market share distribution has shifted with the entry of biosimilars since patent expiries around 2014–2016, leading to price competition and increased market access in multiple regions.

Competitor	Product Name	Market Strategy	Estimated Market Share (2022)
Novo Nordisk	NUTROPIN	Premium-priced biologic, global reach	45%
Sandoz	Omnitrope	Biosimilar, price-sensitive	20%
Pfizer	Somatropin	Established, broad distribution	15%
Eli Lilly	Genotropin	Niche pediatric focus	10%

Financial Trajectory and Revenue Outlook

Revenue Trends

NUTROPIN’s revenue has experienced moderate growth, driven by expanding indications and regions. In 2022, global sales were estimated at approximately USD 1.1 billion. The revenue growth rate is expected to accelerate with increased biosimilarization and expanded access.

Factors Influencing Revenue

• Pricing strategies: Premium pricing in developed markets versus volume-based in emerging regions.
• Market penetration: Success in penetrating pediatric and adult growth hormone markets.
• Regulatory approvals: Faster approvals increase sales opportunities.
• Patent and biosimilar competition: Biosimilars have pressured the price and revenue margins.

Financial Projections (2023–2030)

Year	Estimated Revenue (USD billion)	CAGR
2023	1.2	—
2025	1.5	8.5%
2030	2.0	9.4%

Projected revenues assume continued growth due to expanding indications, biosimilar competition, and geographic expansion.

Regulatory Environment and Policy Impacts

• FDA and EMA Approvals: Product approvals in the US and Europe establish market legitimacy.
• Biosimilar Legislation: Policies favoring biosimilar adoption enhance market access but pressure prices.
• Pricing policies: Cost containment measures in healthcare systems influence revenue.

Key Takeaways

• NUTROPIN operates in a growing, competitive global market dominated by biosimilars.
• Revenue streams are impacted by patent expiries and biosimilar entry, prompting strategic shifts.
• Market growth is driven by increasing diagnosis, expanding access, and favorable policy environments.
• Revenue growth is projected to reach USD 2 billion by 2030, assuming sustained market expansion and pricing strategies.
• Competitive pressures require continuous innovation and geographic diversification.

Frequently Asked Questions

1. How does biosimilar competition impact NUTROPIN’s market share and pricing?
Biosimilars reduce pricing power and shift market share toward lower-cost options, forcing NUTROPIN to adopt more competitive pricing strategies to maintain volume.

2. What are key growth opportunities for NUTROPIN?
Entering emerging markets, expanding adult indications, and leveraging biosimilar proliferation can boost revenue. Approvals for new formulations and delivery methods also contribute.

3. Are regulatory hurdles a significant barrier for NUTROPIN?
Regulatory requirements vary globally but have been manageable for NUTROPIN due to prior approvals. Biosimilar regulations require rigorous comparability data, which can delay market entry.

4. How do healthcare policies influence NUTROPIN's sales?
Cost containment measures in many countries favor biosimilars, influencing prescribing behaviors and reimbursement. Policies encouraging biosimilar substitution can impact brand sales.

5. What strategic moves should Novo Nordisk consider to sustain growth?
Investing in biosimilar development, expanding into underserved regions, and innovating delivery methods will enhance competitiveness and revenue stability.

---

References

[1] Grand View Research. (2023). Growth hormone market size & trends. Retrieved from https://www.grandviewresearch.com/industry-analysis/growth-hormone-market